MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Avidity Biosciences Inc

Closed

SectorHealthcare

30.85 0.46

Overview

Share price change

24h

Current

Min

29.7

Max

31.03

Key metrics

By Trading Economics

Income

-22M

-102M

Sales

637K

3M

EPS

-0.8

Profit margin

-3,439.522

Employees

391

EBITDA

-23M

-120M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+130.32% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

-214M

3.4B

Previous open

30.39

Previous close

30.85

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Avidity Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 kwi 2025, 09:30 UTC

Top News

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Peer Comparison

Price change

Avidity Biosciences Inc Forecast

Price Target

By TipRanks

130.32% upside

12 Months Forecast

Average 67.83 USD  130.32%

High 96 USD

Low 48 USD

Based on 12 Wall Street analysts offering 12 month price targets forAvidity Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

25.8 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.